Enhancement of Peptide Antigenicity for T Cell Priming Using Albumin Binding Peptides
Exclusively Licensed
Invention type: Technology
/
Case number: #19388H
The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
Researchers
Darrell J Irvine
/
Rebecca Holden
/
Kelly Moynihan
/
Bradley L. Pentelute
Departments: Department of Chemistry
Technology Areas: Biotechnology: Synthetic Biology / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
albumin binding peptide conjugates and methods thereof
United States of America | Granted | 11,642,416 -
albumin binding peptide conjugates and methods thereof
China | Published application -
albumin binding peptide conjugates and methods thereof
United States of America | Granted | 11,077,199 -
albumin binding peptide conjugates and methods thereof
European Patent Convention | Published application -
albumin binding peptide conjugates and methods thereof
Japan | Published application -
albumin binding peptide conjugates and methods thereof
Hong Kong | Published application
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.